A $3 billion telehealth company just told investors it wants to be a peptide manufacturer. On its August 10, 2026 second-quarter earnings call, Hims & Hers laid out a plan to launch a "wellness and peptide" category — starting with sermorelin, glutathione and NAD+ before the end of this year — and said it has already put BPC-157 into stability and validation testing so it can move the moment the FDA finishes its rulemaking.
That is the first concrete corporate timeline anyone has attached to the six peptides an FDA advisory panel backed in July. It is also the clearest signal yet that the compounds this site has tracked as research chemicals for years are being priced, staffed and manufactured for a mainstream prescription channel. What it does not do is change anything about where those six compounds are sold this week.
Research-context information only. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon are sold for research purposes only and are not FDA-approved drugs. Corporate statements, regulatory timelines and analyst figures below come from public earnings calls, SEC-reported results and published reporting. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What Hims actually said
The peptide remarks came inside a strong quarter. Hims & Hers reported more than $753 million in Q2 2026 revenue, up roughly 40% year over year, added about 300,000 net new subscribers to reach close to 3 million globally, and raised full-year guidance to a $3.1-3.3 billion range.
On the call, CEO Andrew Dudum split the peptide plan into two tracks. The near-term track is compounds that are already legal to dispense: "we will be moving forward with the wellness and peptide category with a broader set of offerings," he said. "These include things like sermorelin, glutathione, NAD+ and other wellness therapies" — targeted for launch by the end of 2026, alongside injectable and oral testosterone products.
The second track is the six peptides sitting in front of the FDA. Dudum's framing was explicitly conditional: "if and when the FDA does decide to move these peptides to the Category 1 list, we'll be able to move extremely quickly." The preparation is already underway — "we are in the process of actually putting on BPC-157 on the stability and validation testing to be ready shortly and following course with the remainder." Speaking to Glossy, he described the goal as "a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance and ongoing [patient] blood testing."
The reason a telehealth company can talk this way is vertical integration. Hims bought a compounding pharmacy in 2025 and now runs more than 1 million square feet of pharmacy and lab space, and Dudum claimed the company can "manufacture the raw APIs in the U.S." — a capability he argued few competitors have. It hired Dr. Anant Vinjamoori as chief medical officer in June 2026 to build clinical protocols and provider training for exactly this category.
Wall Street was measured. Paul Cerro of Cedar Grove Capital Management told Reuters there is no "release the floodgates demand" for the already-legal starter set the way there would be for the compounds still under review, and Morningstar's Keonhee Kim noted that NAD+ sales are hard to model precisely because a grey market already serves that demand. Longer term, DocShah Financial's Raul Shah projected peptide revenues could clear $1 billion within five to ten years against an addressable market analysts size at $2.2-3.3 billion.
What this changes for buyers
Read the announcement as a timeline, not an availability change. Three things follow from it.
1. The six reviewed peptides are not becoming a Hims product this year. The July 23-24 Pharmacy Compounding Advisory Committee vote backed BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon, and rejected DSIP — but those votes are advisory. The FDA has not issued a final rule, reporting puts that process around a year out, and the agency's next peptide panel is not until February 2027. Dudum's own language ("if and when") concedes the uncertainty. Our full breakdown of what the vote did and did not change is in FDA Peptide Vote Results: What Buyers Need to Know.
2. Nothing about current sourcing moved. Every one of the six is stocked by research-use-only vendors today, at unchanged prices, and no listing on this site changed because of the earnings call. If you were comparing vendors for BPC-157 last week, the comparison is identical this week — see Best BPC-157 Vendors and the per-compound BPC-157 buying guide, or the paired BPC-157 + TB-500 buying guide if you are looking at the recovery stack.
3. The three launching compounds already have both channels. Sermorelin, glutathione and NAD+ are the interesting near-term comparison, because they are the only ones where a prescribed route and a research route will run side by side under the same headline. Those are different products with different economics: a clinical subscription with prescriber oversight and monitoring on one side, per-milligram research vials with vendor-published COAs on the other. If you want to see what the research channel currently charges before the prescribed pricing lands, start with Best Sermorelin Vendors, Best NAD+ Vendors and Best Glutathione Vendors, and the current codes on the deals page.
The broader read is that vertically integrated telehealth is crowding into this category ahead of the rules. Hims is not alone — Celia Rx and BioLongevity Labs have made similar moves toward manufacturing and selling these compounds directly. That competition is the thing most likely to affect pricing over the next 18 months, in either channel.
